Clinical Trial Update: A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and immune response after a third vaccine dose in current and former smokers aged 40–80 with completed status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Disorders

Drugs mentioned

• GlaxoSmithKline vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Disorders | Phase 2 | Status: COMPLETED | Results posted: 2020-11-12